OTCM
REMI
Market cap13kUSD
Jul 09, Last price
0.00USD
Jan 2017
-99.59%
IPO
-99.56%
Name
Remedent Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Remedent, Inc., operating through its various subsidiaries, specializes in the research, development, manufacturing, and distribution of products for both oral hygiene and aesthetic dentistry. The company's core offerings include professional-grade dental veneers and teeth whitening systems, designed for use by dental practitioners as well as for over-the-counter purchase by consumers. Its innovative product portfolio features River8, a pre-fabricated veneer solution that assists dentists in achieving optimal tooth alignment with minimal patient tooth reshaping. Additionally, Remedent supplies GlamSmile veneers, which are exceptionally thin shells bonded to the front surfaces of a patient's teeth. Beyond physical products, the company offers a suite of digital tools and services aimed at enhancing dental practice operations. These include the SmileMe Mirror, an integrated marketing concept that enables quick smile consultations in about ten minutes; SmileSketch, simulation software capable of creating visual previews of potential aesthetic results; and various "Treatment Pages" designed to explain the advantages of specific dental procedures. Furthermore, Remedent provides the Condor, an advanced intra-oral 3D scanning device. The company's expertise also extends to dental implant technologies and related treatment methodologies. Remedent distributes its products to dental professionals in nearly 30 countries, spanning regions such as Asia, Europe, the Middle East, Canada, and the United States, utilizing both its internal sales team and third-party distributors. Founded in 1986, the company's corporate headquarters are located in Ghent, Belgium.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||